Form 8-K Jazz Pharmaceuticals For: May 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Guggenheim Securities Remains Bullish in Wake of Jazz Pharmaceuticals (JAZZ) 1Q15 EPS Miss
May 8, 2015 8:46 AM EDTGuggenheim Securities maintains a Buy status on Jazz Pharmaceuticals, PLC (NASDAQ: JAZZ), with a price target set at $210. This follows an EPS miss from JAZZ in 1Q15. JAZZ reported 1Q15 adjusted diluted EPS of $1.99. This came in $0.15 lower than consensus and $0.18 lower than Guggenheim estimated. Guggenheim believes that... More
